Evan David Seigerman
Stock Analyst at BMO Capital
(3.11)
# 1,771
Out of 4,858 analysts
43
Total ratings
43.59%
Success rate
3.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $800 → $600 | $523.94 | +14.52% | 7 | Jun 2, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $56.03 | +96.32% | 1 | May 23, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $16 → $22 | $21.57 | +1.99% | 1 | May 20, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $21.97 | +27.45% | 1 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $7.70 | +29.87% | 1 | May 5, 2025 | |
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $80.55 | -20.55% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $81.46 | +17.85% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $193.16 | +11.31% | 7 | Feb 3, 2025 | |
| AMGN Amgen | Maintains: Outperform | $362 → $346 | $296.50 | +16.69% | 4 | Jan 29, 2025 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $27 | $9.70 | +178.49% | 3 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $22.00 | +354.55% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $24.81 | +45.13% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.39 | -44.34% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $817.21 | -51.54% | 1 | Sep 6, 2022 |
Regeneron Pharmaceuticals
Jun 2, 2025
Maintains: Outperform
Price Target: $800 → $600
Current: $523.94
Upside: +14.52%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $56.03
Upside: +96.32%
Neurogene
May 20, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $21.57
Upside: +1.99%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $21.97
Upside: +27.45%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $7.70
Upside: +29.87%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $80.55
Upside: -20.55%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $81.46
Upside: +17.85%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $193.16
Upside: +11.31%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $296.50
Upside: +16.69%
Replimune Group
Jan 22, 2025
Maintains: Outperform
Price Target: $18 → $27
Current: $9.70
Upside: +178.49%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $22.00
Upside: +354.55%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $24.81
Upside: +45.13%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.39
Upside: -44.34%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $817.21
Upside: -51.54%